Malignant Otitis Externa

Malignant otitis externa (MOE) — also termed necrotizing otitis externa (NOE) or osteomyelitis of the temporal bone — is a rare, life-threatening invasive infection of the external auditory canal (EAC) that extends to the temporal bone and skull base, predominantly caused by Pseudomonas aeruginosa (>90% of cases). [1-3] It carries historically reported mortality as high as one-third overall and up to 80% when cranial nerves are involved. [4]

• Severe, unrelenting otalgia — classically described as "excruciating" or "pain out of proportion to exam," often worse at night [1][5-6]
• Persistent purulent otorrhea unresponsive to standard topical therapy for ≥2 weeks [1-2]
• Duration and progression: diagnosis is often delayed 6–8 weeks when symptoms are mistakenly attributed to simple otitis externa [5]
• Hearing loss (conductive or sensorineural) [5]
• Headache, trismus, or preauricular swelling suggesting extension [7]
• Ask about prior ear canal manipulation (cotton swabs, cerumen irrigation — a reported iatrogenic trigger) [2][6]
• Ask about water exposure (swimming, ear irrigation) [2]
• Important negatives: Fever is often absent in early disease [5]

• Pain out of proportion to exam findings in a diabetic or immunocompromised patient [1]
• Otitis externa failing topical therapy after 2+ weeks [1]
• Cranial nerve deficits — facial nerve (CN VII) most common; glossopharyngeal (CN IX) and spinal accessory (CN XI) less frequently involved [8-9]
• Periauricular edema, bone exposure, or TMJ pain [7]
• Signs of intracranial extension: altered mental status, seizures, meningismus, new neurological deficits [10]
• Trismus (suggests TMJ or infratemporal fossa involvement) [11]

Causative/contributing medications

• Prior topical fluoroquinolone use may select for ciprofloxacin-resistant Pseudomonas [2]
• Immunosuppressants (chemotherapy, biologics, chronic corticosteroids) increase susceptibility [9-10]

Treatment antibiotics

• First-line empiric: IV antipseudomonal therapy — commonly ciprofloxacin 750 mg PO BID (if susceptible) or IV ceftazidime + ciprofloxacin combination [2][12-13]
• One protocol suggests 3 weeks initial combination therapy (ceftazidime + ciprofloxacin, high doses) followed by 3 weeks ciprofloxacin monotherapy [12]
• Alternative IV agents: piperacillin-tazobactam, meropenem (for resistant organisms or ciprofloxacin failure) [11][14]
• Duration: 6–8 weeks of systemic antipseudomonal therapy, guided by culture/sensitivity [2][5]
• Topical adjuncts: antipseudomonal or acetic acid otic drops [5]

Cautions

• Ciprofloxacin resistance is emerging — always obtain cultures with antibiogram [2][9]
• Aminoglycosides carry ototoxicity risk in this population
• Avoid ear canal irrigation in diabetic/immunocompromised patients — may predispose to NOE [8]

• Strict glycemic control is essential and directly impacts outcomes [9][15]
• Diabetic diet optimization; endocrinology consultation for poorly controlled diabetes
• Adequate hydration and nutrition to support immune function
• No specific dietary triggers, but uncontrolled hyperglycemia is a major modifiable risk factor

• ENT: Otalgia severity, otorrhea character/duration, hearing changes, tinnitus, vertigo
• Neurological: Facial asymmetry/weakness, dysphagia, hoarseness, shoulder weakness (cranial nerves VII, IX, X, XI) [8]
• Constitutional: Fever (often absent early), night sweats, weight loss (consider malignancy mimic)
• MSK: Jaw pain, trismus, TMJ tenderness [7][11]
• Vascular: Headache pattern changes (consider sigmoid sinus thrombosis)

• Diabetes control: HbA1c, medication adherence, recent glucose trends
• Immunosuppression history: HIV status, chemotherapy, organ transplant, chronic steroid use [2][10]
• Prior ear interventions: Recent cerumen removal, ear irrigation, hearing aid use [2][6]
• Prior episodes of otitis externa or MOE (recurrence rate is notable) [11]
• Family history is generally not contributory, though familial diabetes risk is relevant

• Diabetes mellitus (poorly controlled) — present in 65–90% of cases [7][16]
• Advanced age — mean age ~62–77 years [16-17]
• Male sex — ~62–74% male predominance [7][16]
• Immunosuppression: HIV/AIDS, chemotherapy, organ transplant, chronic corticosteroids [2][10]
• History of radiation therapy to the head/neck [8]
• Ear canal trauma: cotton swab use, hearing aids, ear irrigation [2][6]
• Water exposure (swimming, ear irrigation converting acidic EAC pH to alkaline) [10]
• Chronic kidney disease, hypertension, and ischemic heart disease are common comorbidities [16]

• Squamous cell carcinoma of the EAC — the most critical mimic; tissue biopsy is recommended to rule out malignancy [5-6]
• Uncomplicated acute otitis externa — responds to topical therapy, no granulation tissue or bone involvement [18]
• Chronic otitis externa — itching predominant, lasts >3 months, no osteomyelitis [18]
• Ramsay Hunt syndrome — herpetic vesicles in canal, facial paralysis, loss of taste; treat with antivirals [18]
• Cholesteatoma of the EAC — can mimic on imaging [17]
• Chronic suppurative otitis media — chronic otorrhea with nonintact tympanic membrane [18]
• Otomycosis (Aspergillus, Candida) — itching predominant, fungal elements on otoscopy; can coexist with MOE [10]
• Referred pain (dental, TMJ, pharyngeal) — normal ear exam [18]
• Wegener granulomatosis (GPA) — granulomatous inflammation, may involve temporal bone

• Diabetes mellitus — type and control (HbA1c), complications
• Prior episodes of otitis externa or MOE
• HIV/AIDS status and CD4 count
• Malignancy and chemotherapy history
• Prior head/neck radiation
• Chronic kidney disease (affects antibiotic dosing)
• Prior ear surgeries, tympanostomy tubes [8]
• Hearing aid use

Vital signs

• Fever may be absent early; when present, suggests advanced disease [5]
• Tachycardia may indicate sepsis

Otoscopic exam

• Granulation tissue at the bony-cartilaginous junction — hallmark finding, though not always present [3][8]
• Edematous, erythematous EAC with purulent otorrhea [1]
• Necrotic tissue in the canal [18]
• Assess tympanic membrane integrity

Focused exam

• Cranial nerve exam — especially CN VII (facial nerve): ask patient to smile, raise eyebrows, close eyes tightly [1][8]
• CN IX, X, XI, XII assessment (gag reflex, voice quality, shoulder shrug, tongue protrusion) [8]
• Tragal and pinnal tenderness
• Periauricular and preauricular lymphadenopathy/swelling
• TMJ tenderness, trismus [7]
• Parotid gland assessment
• Mastoid tenderness

• ESR — highly useful; ESR >26 mm/h has a positive likelihood ratio of 10.15 for NOE (AUC 0.92) [19]
• CRP — CRP >10 mg/L has a positive likelihood ratio of 8.25 [19]
• If both ESR and CRP are normal, an alternative diagnosis should be sought [19]
• EAC culture with Gram stain — essential; send for aerobic bacterial culture; consider fungal culture [20]
• Tissue biopsy of granulation tissue — for culture and to rule out squamous cell carcinoma [5-6]
• CBC — leukocytosis (may be absent in immunocompromised)
• BMP — renal function (affects antibiotic dosing), glucose
• HbA1c — assess diabetic control
• Blood cultures — if febrile or septic

First-line

• CT temporal bone with IV contrast — most commonly used initial imaging; excellent for demonstrating bone erosion, soft tissue changes at skull base [1][10]
• CT was used in 73% of cases as the primary diagnostic modality [10]
• However, CT can be negative in early disease — 50% of patients with negative CT were ultimately diagnosed with NOE on further imaging [17]

Gold standard for diagnosis

• Tc-99m bone scintigraphy — highly sensitive (positive in 100% of NOE cases); useful when CT is negative or equivocal [10][21]
• Limitation: remains positive after clinical resolution (cannot be used to confirm cure) [10]

For treatment monitoring

• Gallium-67 scintigraphy — normalizes with infection resolution; used to guide antibiotic cessation [10]
• FDG-PET/CT — emerging as an alternative for both diagnosis and treatment monitoring [22]

For intracranial complications

• MRI with gadolinium[5][10]

When imaging is unnecessary

• [10]

Diagnostic criteria (combination of)

• Clinical findings (severe otalgia, otorrhea, granulation tissue in immunocompromised host)
• Elevated ESR [2]
• Positive EAC culture (Pseudomonas in >90%) [2]
• Radiographic evidence of soft tissue/bone involvement [2]

Point-of-care

• Bedside otoscopy — look for granulation tissue at bony-cartilaginous junction
• Bedside glucose/HbA1c

Procedures

• [5][20]

• ECG is not routinely indicated for MOE itself
• Consider ECG if:
  • Fluoroquinolone therapy planned (QTc prolongation risk, especially with concurrent QT-prolonging medications)
  • Elderly patient with cardiac comorbidities (common in this population) [16]
  • Sepsis or hemodynamic instability

MOE is a medical emergency with high morbidity and potential mortality. [1][18] The typical patient is an elderly diabetic male presenting with severe, unrelenting otalgia and purulent otorrhea unresponsive to topical therapy. The diagnosis requires a high index of suspicion, as early disease may appear similar to uncomplicated otitis externa.

Severity stratification

• Early/localized: EAC inflammation with granulation tissue, no cranial nerve involvement, positive Tc-99m scan
• Advanced/extensive: Skull base osteomyelitis, cranial nerve palsies (facial nerve most common), periauricular extension [7]
• Intracranial: Meningitis, cerebral abscess, sigmoid sinus thrombosis — highest mortality [10]

• Facial nerve paralysis (most common CN deficit) [15]
• Skull base osteomyelitis [10]
• Meningitis, cerebritis, intracranial abscess [10]
• Jugular vein/sigmoid sinus thrombosis [4]
• Contralateral spread
• Recurrence (notable risk, especially with inadequate treatment duration) [11]

Initial stabilization (ED)

• IV access, pain management (often requires opioids given severity)
• Obtain EAC cultures before starting antibiotics
• Check glucose, initiate glycemic control

Antibiotic therapy

• Empiric IV antipseudomonal coverage — start immediately upon clinical suspicion [1]
• Preferred regimen: Combination of IV ceftazidime + oral/IV ciprofloxacin initially, transitioning to ciprofloxacin monotherapy after 3 weeks if susceptible (total 6 weeks) [12]
• Alternative: Ciprofloxacin 750 mg PO BID monotherapy for 6–8 weeks (for less severe, susceptible cases) [2][13]
• Resistant organisms: Meropenem, piperacillin-tazobactam, or antibiogram-guided therapy [9][11]
• Fungal MOE: Systemic antifungals (voriconazole, amphotericin B) if Aspergillus or Candida identified [10]
• Topical antipseudomonal or acetic acid drops as adjunct [5]

Surgical management

• Debridement of necrotic/granulation tissue by ENT [5][9]
• Extensive surgery reserved for refractory cases or facial nerve involvement [15]

Adjunctive

• Glycemic optimization — endocrinology consultation [9]
• Hyperbaric oxygen therapy — considered in refractory cases, though a Cochrane review found no RCTs to support its use [4][11]
• Correction of immunosuppression when possible [6]

Admission criteria (most patients require admission): [1][18]

• All patients with suspected or confirmed MOE
• Cranial nerve deficits
• Need for IV antibiotics
• Poorly controlled diabetes requiring inpatient optimization
• Intracranial complications
• Hemodynamic instability or sepsis

Observation

Discharge considerations

• [13]

Specialist consultation triggers

• ENT (otolaryngology) — consult early in all suspected cases for debridement, biopsy, and ongoing management [1][5]
• Infectious disease — for antibiotic guidance, especially resistant organisms or prolonged therapy [12]
• Endocrinology — for diabetic optimization
• Neurosurgery — if intracranial extension suspected

Follow-up timing

• Close ENT follow-up within 1 week of discharge
• Serial ESR/CRP monitoring to assess treatment response [19]
• Gallium-67 scan or FDG-PET/CT after 6 weeks of therapy to confirm resolution before stopping antibiotics [10][22]
• Follow-up for at least 1 year post-treatment given recurrence risk [15]

Return precautions — instruct patients to return immediately for:

• Worsening ear pain despite antibiotics
• New facial weakness or drooping
• Difficulty swallowing, hoarseness, or new neurological symptoms
• Fever, rigors, or altered mental status
• Inability to tolerate oral antibiotics (nausea/vomiting)

Patient counseling

• Avoid ear canal manipulation (no cotton swabs, no ear irrigation) [6]
• Minimize water exposure to the ear canal [6]
• Strict medication adherence — full antibiotic course is critical
• Diabetic control is essential to prevent recurrence [9][15]

Expected recovery

• Clinical improvement typically within 1–2 weeks of appropriate therapy, but full treatment course (6–8 weeks) is mandatory [2][12]
• Cranial nerve palsies may or may not recover fully
• Recurrence is possible, particularly with inadequate treatment duration or persistent immunosuppression [11]

Images

1. An Emergency Medicine-Focused Review of Malignant Otitis Externa. — Long DA, Koyfman A, Long B. The American Journal of Emergency Medicine. 2020.

2. The Changing Face of Malignant (Necrotising) External Otitis: Clinical, Radiological, and Anatomic Correlations. — Rubin Grandis J, Branstetter BF, Yu VL. The Lancet. Infectious Diseases. 2004.

3. Otitis Externa and Malignant Otitis Externa-for the Hospitalist/­Internist. — Patel S, Owen GS, Vivas EX. The Medical Clinics of North America. 2026.

4. Hyperbaric Oxygen as an Adjuvant Treatment for Malignant Otitis Externa. — Phillips JS, Jones SE. The Cochrane Database of Systematic Reviews. 2013.

5. Infections in Patients with Diabetes Mellitus. — Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. The New England Journal of Medicine. 1999.

6. Necrotizing (Malignant) External Otitis. — Handzel O, Halperin D. American Family Physician. 2003.

7. Epidemiology and Risk Factors for Extension of Necrotizing Otitis Externa. — Krawiec E, Brenet E, Truong F, et al. European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies : Affiliated With the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2024.

8. Clinical Practice Guideline: Acute Otitis Externa. — Rosenfeld RM, Schwartz SR, Cannon CR, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2014.

9. Patient Cases With Malignant Otitis Externa at the University Clinic of Ludwig Maximilians University Munich From 2009 Until 2020. — Stocker M, Hempel JM. Scientific Reports. 2025.

10. ACR Appropriateness Criteria® Inflammatory Ear Disease. — Agarwal M, Juliano AF, Hagiwara M, et al. Journal of the American College of Radiology : JACR. 2025.

11. Isolated Temporomandibular Joint Involvement in a Rare Case of Malignant Otitis Externa. — Celleoğlu S, Yazici D. The Journal of Craniofacial Surgery. 2025.

12. Antibiotic Therapy in Necrotising External Otitis: Case Series of 32 Patients and Review of the Literature. — Pulcini C, Mahdyoun P, Cua E, et al. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2012.

13. Ciprofloxacin Treatment of Malignant External Otitis. — Sadé J, Lang R, Goshen S, Kitzes-Cohen R. The American Journal of Medicine. 1989.

14. Necrotising Otitis Externa: Clinical Profile and Management Protocol. — Lambor DV, Das CP, Goel HC, et al. The Journal of Laryngology and Otology. 2013.

15. Malignant Otitis Externa: An Updated Review. — Treviño González JL, Reyes Suárez LL, Hernández de León JE. American Journal of Otolaryngology. 2021.

16. Evaluation of the Clinical and Radiological Features of Patients With Malignant Otitis Externa (MOE). — Tabashiri A, Allahverdi Nazhand H, Fathy M, et al. BMC Infectious Diseases. 2025.

17. Refining Necrotising Otitis Externa Management: A Follow-Up Study on a Departmental Algorithm and the Role of Nuclear Medicine Imaging. — Haleem AH, Shahidi S, Hilton JM, et al. American Journal of Otolaryngology. 2025.

18. Acute Otitis Externa: Rapid Evidence Review. — Jackson EA, Geer K. American Family Physician. 2023.

19. Necrotizing External Otitis: Diagnostic Clues in the Emergency Department. — Vaca M, Medina MM, Cordero AI, et al. European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies : Affiliated With the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2024.

20. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

21. Malignant External Otitis: Early Scintigraphic Detection. — Strashun AM, Nejatheim M, Goldsmith SJ. Radiology. 1984.

22. FDG-PET/­CT for Diagnosis and Follow-Up of Necrotizing (Malignant) External Otitis. — Stern Shavit S, Bernstine H, Sopov V, Nageris B, Hilly O. The Laryngoscope. 2019.